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Elina Petkova1, Valentina Petkova1*, Maia Konstantinova2 and Guenka Petrova1Abstract
Background: The objective of this study is to assess the cost of using continuous subcutaneous insulin infusion to
treat children with type-1diabetes in Bulgaria, considering changes in body mass index (BMI) and the glycated
hemoglobin. The study was performed from the perspective of the Bulgarian National Health Insurance Fund (NHIF)
and patients.
Methods: A total of 34 pediatric type-1-diabetes patients were observed for 7 months, divided into 2 groups – on
pumps and on insulin analogue therapy. Patient demographic data, BMI and glycated hemoglobin level were
obtained and recorded. The cost of insulin, pumps, and consumables were calculated and compared with changes
in glycated hemoglobin level. The incremental cost-effectiveness ratio was below the threshold value of gross
domestic product per capita.
Results: The results were sensitive to changes in glycated hemoglobin level. Improvements associated with
glycemic control led to a reduced glycated hemoglobin level that could ensure good diabetes management, but
its influence on BMI in growing children remains unclear.
Conclusion: Continuous subcutaneous insulin infusion appears to be more cost-effective for the Bulgarian pediatric
population and health care system.
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Type-1-diabetes (T1DM) patients treated with unmodified
regular human insulin (RHI) rarely achieve their glycemic
target and often suffer from postprandial hyperglycemic
incidents, together with an increased risk of hypoglycemia
in the post-absorptive period [1]. Recent meta-analyses in
the literature have found improved glycemic control with
continuous subcutaneous insulin infusion (CSII) com-
pared with multiple daily injections (MDI) of insulin for
patients with diabetes mellitus. For example, in Australia,
CSII is predominantly used in type-1-diabetes mellitus* Correspondence: petkovav1972@yahoo.com
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reproduction in any medium, provided the orpatient populations [2]. Continuous subcutaneous insulin
infusion (CSII) is considered an option for type-1diabetic
patients unsatisfactorily controlled with multiple daily
injections (MDI). Short-acting analogs are superior to
regular human insulin in CSII. There is evidence
supporting the advantages of short-acting analog-based
CSII over MDI in type-1 diabetes. The reduction of
glycated hemoglobin (HbA1c) level with CSII was evi-
dent in trials enrolling patients with mean age greater
than 10 years [3].
The main goals for managing children with type-1-
diabetes mellitus include achieving near-normal blood
sugar levels, minimizing hypoglycemic incidents, opti-
mizing quality of life, and preventing or delaying long-
term complications. Continuous subcutaneous insulinl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of the main findings from the published studies
Authors Objective Methodology Results Conclusions
Plotnick
et al. [8]
To evaluate the safety and effectiveness of
insulin pump therapy in children and
adolescents with type-1diabetes.
All patients who started insulin pump therapy
between 1 January 1990 and 31 December
2000 were included in this study. Medical
records were reviewed for 95 patients, ages 4–
18 years at pump start. The mean (SD) age was
12.0-3.1 years, and children under the age of
10 years comprised 29% of the group. Patients
and families chose insulin pump therapy for
several reasons, including better control, less
blood glucose variability, fewer injections and
improvement in lifestyle flexibility. HbA1c was
measured at each visit by cation-exchange
high-performance liquid chromatography.
There was a small but significant decrease in
HbA1c at 3–6 months after starting with pump
(7.7 vs. 7.5%; P < 0.03). HbA1c levels then
gradually increased and remained elevated
after 1 year of follow- up. This association was
confounded by age and diabetes duration,
both of which were associated with higher
HbA1c levels. After adjusting for duration and
age, mean HbA1c after pump start was
significantly lower than before pump start (7.7
vs. 8.1%; P <0.001). There were fewer
hypoglycemic events after pump start (12 vs.
17, rate ratio 0.46, 95% CI 0.21–1.01).
Insulin pump use was safe and effective.
After adjusting for age and duration of
diabetes, HbA1c was in fact lower after
pump placement.
Both monitoring frequency and parental
involvement were significantly associated
with lower HbA1c levels.
Bode
et. al. [9]
To compare multiple daily injections (MDI),
and CSII and to assess the effects on quality
of life.
Comparative analysis In adults and adolescents with type-1diabetes,
CSII has been shown to lower HbA1c levels,
reduce the frequency of severe hypoglycemia
and limit excessive weight gain versus MDI
without increasing the risk of diabetic
ketoacidosis. The effectiveness of CSII and
improvements in pump technology have
fueled a dramatic increase in the use of this
therapy.
Insulin pump or continuous subcutaneous
insulin infusion (CSII) therapy provides a
treatment option that can dramatically aid
in achieving all of these goals.
Wilson
et al. [10]
To compare continuous subcutaneous insulin
infusion (CSII), and continuing multiple daily
injections (MDIs), in respect to their safety in
young children, glycemic control,
hypoglycemia and quality of life.
A randomized 1-year feasibility trial comparing
CSII with continuing MDIs in preschool children
with a history of type-1diabetes for at least
6 months’ duration. Prospective outcomes
included measures of overall glycemic control
(HbA1c and continuous glucose monitoring
system), the incidence of severe hypoglycemia
and diabetic ketoacidosis, the percent of
glucose values below 3.9 mmol/l, and the
parents’ report of quality of life.
The 19 subjects’ ages ranged from 1.7 to 6.1
(mean 3.6) years, duration of diabetes ranged
from 0.6 to 2.6 (mean 1.4) years, and baseline
HbA1c ranged from 6.7 to 9.6% (mean 7.9%).
Nine subjects were randomized to start CSII and
10 to continue on MDI. Overall metabolic
control, diabetes quality of life, and the incidence
of hypoglycemia were similar in the two groups.
No subject had diabetic ketoacidosis, while one
subject in each group had an episode of severe
hypoglycemia. No CSII subject discontinued
using the pump during or after the study.
CSII can be a safe and effective method to
deliver insulin in young children.
Cohen
et al. [2]
To project long-term costs and outcomes of
CSII compared with MDI in adult and
adolescent T1DM.
The study modelled analysis utilizing a lifetime
horizon in adult and adolescent specialty-care
type-1-diabetes patient populations from
Australia. Published diabetes complication costs,
treatment costs and discount rates of 5.0% per
annum were applied to costs and clinical
outcomes. A lifetime horizon was used,
considering only direct medical costs and
excluding indirect and non-medical costs. The
validated CORE diabetes model employs
standard Markov/Monte Carlo simulation
techniques.
Mean direct lifetime outcomes were $A 34 642
higher with CSII treatment than with MDI for
adult patients and $A 41 779 for adolescent
patients. Treatment with CSII is associated with
an improvement in life expectancy of
0.393 years for adults compared with MDI and
0.537 years for adolescents. The corresponding
gains in QALYs were 0.467 QALYs and 0.560
QALYs for adults and adolescents, respectively.
This produced incremental cost effectiveness
ratios (ICERs) of $A88 220 and $A 77851 per
life-year gained for CSII compared with MDI for
adult and adolescent T1DM.
The analysis suggests that CSII is associated
with ICERs in the range of $A53 022–259
646 per QALY gained with most ICERs
representing a significant savings in


















Table 2 Patient demographic
Gender Age (months) Months with diabetes
Insulin Males (n = 10) 112.41 ± 42.705 41.71 ± 22.79
Females (n = 7)
Pumps Males (n = 9) 113.82 ± 49.054 66.65 ± 41.07
Females (n = 8)
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achieving all of these goals in all ages of children [4].
European Union countries reimburse insulin therapy
for individuals with health insurance, but for CSII reim-
bursement, a variety of approaches exist [5-7]. The ob-
jective of this study is to assess the cost of using CSII of
insulin to treat children with type-1diabetes in Bulgaria
and to compare it with the changes in BMI and HbA1c.
The study was performed from the perspective of the
Bulgarian NHIF and patients. The main study question
discussed is “will the use of CSII be cost-effective for
the Bulgarian health care system?”
Methods
Literature search
PubMed was searched using keywords CSII, type-
1diabetes, pediatric population and all articles analyzing
the safety, efficacy, and cost-effectiveness of CSII usage
in the pediatric population were selected. In total, 4 stud-
ies were selected and their objectives, methodologies, re-
sults and conclusions were compared [2,8-10].
Type of the CSII usage study
A combined retrospective and prospective analysis of
children patient records after the introduction of CSII
was performed based on the patients’ records and obser-
vation. This study was performed at the Endocrinology
Clinic of University pediatric hospital of the Medical
University, Sofia. It was reviewed and approved by the
Ethics committee of the Science medical council of the
Medical University in Sofia.
Patient selection
A total of 34 children with type-1diabetes were observed
divided into two groups: with an active group using CSII
and a control group using analogue insulin therapy with
a pen device. Thirty children in the country use CSII,
and of these, 17 were surveyed, after their parents signed
informed-consent forms. The children were consecutively
recruited from the end of 2007 when the first pumps wereTable 3 Changes in the study outcomes
BMI before BMI after BMI difference H
Insulin 18 ± 2.716 19.47 ± 2.125 1,47 ± 2,71 1
Pumps 17 ± 2.739 19.65 ± 1.272 2,65 ± 1,53 8administered. The active group included all children
who began using the CSII pumps during the period
2007–2011 when the data collection began. Also since
2010, all children were transferred to real time insulin
pumps; therefore at the moment of observation, they all
used the same type of pump from the same manufacturer.
The control group was formed after reviewing patient
records and random selection according to age, duration
of diabetes, entrance BMI and HbA1c level. Their parents
also signed informed-consent forms.
Data collection
The data was collected by observing the therapeutic ef-
fects on both groups from the Endocrinology pediatric
clinic from 01.02.2012 to 31.08.2012 (7 months). During
this period, we measured the diabetes maintenance phase
after CSII introduction. Data for the selected children
was collected on their demographics, age, gender,
weight, duration of disease, therapeutic schema (CSII or
analogue insulin treatment with a pen device) and
HbA1c before the inclusion in the pump program, and
at the end of the observation.
Cost – effectiveness analysis
For both groups of children, the health care resources
used by them were recorded, namely insulin, pumps (1 for
4 years), consumables for pumps (6–10 sets and 6–10 res-
ervoirs), strips (n = 1100 per patient per year), glucometers
(1 for 5 years including sensor prices), GP and endocrin-
ology visits, and hospitalization due to diabetes. Sensors
were used from 7 to 10 days. Yearly costs of CSII, blood
glucose monitoring systems, insulin therapy, and strips
were calculated by multiplying the number of resources
used by their prices. Prices of pumps and blood glucose
monitoring systems were collected from the manufac-
turers’ websites. To calculate the yearly pump costs, the
prices were divided by 4, which is recommended by the
manufacturers as the period of use for initial users [11].
All other costs were taken from the Bulgarian NHIF tariff
[12]. Costs are presented in Bulgarian leva (BGN). At the
time, the exchange rate was 1 Euro: 1.95 BGN.
The primary outcome observed was the change in
HbA(1c) before the pump introduction and at the end
of the study. The secondary outcome observed was the
BMI change during the same period. In this pilot study
we did not include the hypoglycemia episodes due to
lack of data for all children. Children were introduced
to pumps in different time periods, and in order tobA1c (%) before HbA1c (%) after HbA1c (%) difference
0.11 ± 1.46 9.01 ± 2.50 0.52 ± 0.41
.99 ± 0.66 7,1 ± 0,67 1.25 ± 0.99






Insulin 700.92 ± 224.304 225 925,92
Pumps 453.96 ± 144 1962,5 425 3360 6201,46
Table 5 Cost –effectiveness analysis (BGN)
Total cost Change in HbA1c CER ICER
Insulin 925,92 0.52 ± 0.41 1780,61
Pumps 6201,46 1.25 ± 0.99 4961,17 7226,77
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level, the total decrease during the period was divided
into the duration of the period when the particular child
was using the pump. Finally the average decrease for
both groups was calculated.
Cost effectiveness ratio (CER) was calculated by dividing
the yearly cost of the health care resources and the
changes in the HbA1c level. Incremental cost-effectiveness
ratio (ICER) was also calculated by dividing the differences
in costs between the active and control group with the
differences in the HbA1c level.
Sensitivity analysis
To test the robustness of the results, a one-way sensitiv-
ity analysis was performed by consecutively varying the
changes in the HbA1c within the standard deviation
interval for both groups of patients with 0.05.
Statistical analysis
Descriptive statistics were applied to the patient’s char-
acteristic and outcomes. A T-test analysis was also
performed to test the statistical significance in the out-
come changes.
Results
Analysis of published studies
There are 4 studies in the literature that discuss the
efficacy, safety and/or cost-effectiveness of CSII usage
in the pediatric population – Table 1. The number of
observed patients varied from 19 to 95. All of these
studies measured the decrease in HbA1C, and some, in
addition, focused on patients’ demographic character-
istics, glucose level, hypoglycemia, and quality of life.
All of the studies conclude that CSII is safe and effective,
leading to greater decreases in HbA1c levels, allowing for
improved quality of life, decreased hypoglycemic events
and improved child and parent adherence as shown in
Table 1.
The published studies define the HbA1c level as the
widely accepted measure of diabetes control in pediatric
practice. Positive therapeutic results after CSII introduc-
tion that might lead to better long-term outcomes are
observed.
Results of the national study
The University pediatric clinic has been introducing CSII
on the request of the parents, with only 30 children hav-
ing applied so far. From 1999 to 2011, 17 children with
diabetes type-1 were observed mean age 113,82 months
in the active group and 112.,41 in the control group.
The duration of diabetes was a little lower in the control
group – Table 2.
In both groups, BMI increased and the change was
higher in the active group with lower standard deviation(SD), meaning that these children maintained stable
growth. A stable and significant decrease in the HbA1c
level is observed in the group of patients using CSII
(1.25 ± 0.99). It is also evident that the CSII groups
maintained close to target levels of HbA1c (6,5%) at the
end of the study, while in the control group, the target
control was not observed – Table 3.
The CSII price of the blood glucose monitoring system
was 7850 BGN (4025,64 Euro) thus reaching 1962,50
BGN (1006,41 Euro) per patient per year – Table 4. The
transmitter cost was 425 BGN (217,95 Euro). The test
strips cost 1039,35 BGN (533 Euro) year (1100 strips per
year) and their average cost according to the duration of
the disease was 7369,93 BGN (3779.45 Euro) from onset
and diagnosis. This cost was equal in both groups per
protocol and was not included in the cost analysis. Insu-
lin usage due to the strict control was lower in the group
of children with CSII and therefore their yearly cost of
insulin therapy was lower (Table 3). The total cost of
therapy in the group of CSII users was higher mainly
due to the CSII pumps and related consumables.
The cost per unit of decrease in HbA1c in the control
group was 1780,91 BGN (913.13 Euro) and almost 3.5
times higher in the group using CSII – Table 5. But the
ICER showing the additional cost per unit of decrease in
HbA1c was lower than the recommended threshold of
yearly gross domestic product (GDP) per capita. This
means that CSII usage is cost-effective for the Bulgarian
health care system.
The results were sensitive to changes in the HbA1c
level in both groups. The ICER ratio for CSII pumps
remained below the threshold value when the difference
in HbA1c level was below 0,42% in the control group
and 1,30% in the active group. When the differences in
the HbA1c level in the control group increased, the
ICER also increased, while in the active group, the op-
posite occurred. This means that the therapy with the
pumps is an efficient alternative for the health care sys-
tem in Bulgaria when children manage to decrease their
HbA1c level by more than 1.30% (Figure 1).
Figure 1 ICER change in active and control group when differences in HbA1c change.
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Continuous subcutaneous insulin infusion (CSII) systems
are of a limited usage because they are not reimbursed by
the Health Insurance Fund in Bulgaria. No official criteria
for CSII usage in child populations have been established
and only parents with sufficiently high income are able to
afford such a therapeutic approach. In this sense, evalu-
ation of the cost-effectiveness of CSII usage is influenced
by a number of factors, such as health insurance policy,
parents’ preferences, and therapeutic standards. Our study
shows that the usage of CSII with child populations is an
efficient therapy and confirms similar findings reported in
the literature on improvements in terms of better meta-
bolic control, reduced rates of complications and better
quality of life [2,13].
The study also shows that the children using CSII
manage to maintain stable and target HbA1c levels,
which are preconditions for better diabetes management
(UKPDS, DCCT). The studies of the CSII usage in child
populations are very limited for comparing long-term
results in detail, but bearing in mind the evidence for
the adult population, it can be predicted that strict and
reliable disease control for children will support their
long-term survival.
One limitation of this study is the small patient sample
due to the limited number of children on CSII in
Bulgaria, but it includes more than 57% of all the CSII
users in the country, which ensures reliable results for
the whole group. The number of the patients is twice
as high as Wilsons’ study [8]. Some of the costs are not
included in the analysis (strips, physicians visits, hospi-
talizations) because they were equal for the both
groups and would not change the ICER. We did not
calculate the cost-effectiveness of CSII pumps related
to the second observed outcome – BMI, because an
increase in children’s weight as a result of their normal
developmental growth was observed in the both groups.Our study aimed to provide evidence for the Bulgarian
NHIF to include CSII within the reimbursement system.
Strict criteria for appropriate selection of children must be
developed, as well as cost controls in order to make the
final decision. The reimbursement practice in some coun-
tries provides such evidence, as in Serbia, where insurance
authorities are paying for consumables and patients’ fam-
ilies are paying for pumps. In countries with high GDP,
CSII is included within the scope of the reimbursement
system [7].
Conclusion
Improvements in glycemic control associated with CSII
led to reduced HbA(1c), which can ensure good dia-
betes management, but its control over BMI in growing
children remains unclear. CSII pumps appear to be
cost-effective for the Bulgarian pediatric population and
health care system.
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